ArticleFrontiers in medicine2026
TNM stage I pancreatic ductal adenocarcinoma patients without pathological risk may drive limited benefit from adjuvant chemotherapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In this study, we identified pathological risk factors as key determinants of whether patients with pancreatic ductal adenocarcinoma (PDAC) can benefit from adjuvant chemotherapy following radical resection. Methods: This single-center retrospective study enrolled 520 patients who underwent curative-intent resection for pancreatic ductal adenocarcinoma between 2011 and 2018. To minimize potential selection bias and confounding effects, propensity score matching (PSM) was performed using a 1:2 nearest-neighbor matching algorithm without replacement, with a caliper of 0.2 standard deviations of the logit propensity score. After matching, the patients were stratified based on the presence or absence of pathological risk factors, allowing for a comprehensive evaluation of how these factors influence the efficacy of adjuvant chemotherapy. Results: Based on the analysis for the whole study, the results showed that adjuvant chemotherapy could significantly improve the overall survival (OS) ( Conclusion: The results of this study indicate that pathological risk factors play a key role in postoperative adjuvant chemotherapy for PDAC patients in TNM stage I. For patients in TNM stage I who harbored pathological risk factors, postoperative adjuvant chemotherapy was associated with a significant survival benefit. However, among those without pathological risk factors, no statistically significant association was observed between adjuvant chemotherapy and improved survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.